The Money Question: Cost-Effectiveness in Drug Discovery

Apr 3, 2012, 02:20 AM by Michael Croft

Xconomy | Cost-effectiveness in biotech and drug discovery can no longer be a secondary consideration, but the cost of drugs to patients is still not frequently discussed.

April 3, 2012 | Cost-effectiveness in biotech and drug discovery can no longer be a secondary consideration, but the cost of drugs to patients is still not frequently discussed. No matter how effective a drug candidate is, the eventual costs to patients or payors must be a primary part of the drug discovery conversation. Xconomy